Taisho Pharmaceutical launches LOCOA, a transdermal patch in Malaysia

Taisho Pharmaceutical has launched LOCOA (Esflurbiprofen), a transdermal patch in Malaysia in conjunction of World Arthritis Day 2021 on October 12th, 2021.

The launch was officiated by Dr. Suhail Suresh, Consultant Orthopaedic from Sunway Medical Centre and witnessed by Mr. Tomoyuki Katsuta. The patch is created to help the osteoarthritis patients to manage their pain that may be troubling their movements and daily activities.

Osteoarthritis is one of the most common joint disease and it is recognised as among the highest contributor of global disabilities. “Once someone’s being diagnosed with osteoarthritis, there’s potential for the pain to occur more frequently thus it is vital to take preventive measures and while there is no cure for this incapacitating illness, treatments have improved significantly in the recent years and there’s a clear benefit in starting treatment at an early stage”, said Chief Operating Officer of HOE Pharmaceuticals, a subsidiary of Taisho Pharmaceutical Group, Mr. Tomoyuki Katsuta. 

LOCOA has been approved since 2016 in Japan and it was developed with the intention of giving more option to osteoarthritis patients in managing their pain more effectively. The goal of treatment in osteoarthritis is to reduce joint pain and inflammation while improving and maintaining joint function. Developed in Japan, LOCOA is a tape type patch with COX inhibition that is used to treat inflammation and pain for osteoarthritis. 

It is worth noting that Taisho Pharmaceutical has decided to choose Malaysia as the first country outside Japan to introduce LOCOA. According to the Department of Statistics Malaysia (DOSM), the number of people aged 65 years and above in Malaysia has increased steadily since the 1970s. Seeing the potential of Malaysia to be a country with high level of health consciousness, Taisho Pharmaceutical believes by introducing LOCOA here, it would also benefit elderly Malaysian population. 

LOCOA also offers high transdermal absorption ratio. LOCOA has shown to provide high analgesic improvement. Besides resting, stretching, weight loss management, physical therapy, occupational therapy or mechanical support devices, such as knee braces, osteoarthritis patients have an option with LOCOA to manage their pain. 

LOCOA is proven to be safe on having a safety study based on a 52-weeks treatment and has minimal Adverse Drug Reactions (ADR). LOCOA has a daily dosing of one patch only as the plasma concentration is well maintained throughout 24 hours. 

Mr. Tomoyuki Katsuta also added, “We hope that patients who are on LOCOA will be able to live their day-to-day life close to normal again without having to bear much pain”. LOCOA now can be found at all major pharmacies and healthcare facilities near you. 

Credited to Taisho Pharmaceutical

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: